When the distributions of GAS5 genetic polymorphism were analyzed among all cancer stage subdivisions (stage I, II, III and IV) in patients with uterine cervical cancer, we found that patients with genotype TC in GAS5 rs55829688 had more risk to have stage II (OR: 2.69, 95% CI: 1.08-6.70; p=0.033) and stage III (OR: 15.56, 95% CI: 1.80-134.24; p=0.013) using TT as a reference (Supplement Table 1). The gene discussed is GAS5; the disease is cancer.